Fragment‐based drug discovery—the importance of high‐quality molecule libraries

M Bon, A Bilsland, J Bower, K McAulay - Molecular Oncology, 2022 - Wiley Online Library
Fragment‐based drug discovery (FBDD) is now established as a complementary approach
to high‐throughput screening (HTS). Contrary to HTS, where large libraries of drug‐like …

Fragment-to-lead medicinal chemistry publications in 2021

L Walsh, DA Erlanson, IJP de Esch… - Journal of medicinal …, 2023 - ACS Publications
This Perspective is the seventh in an annual series that summarizes successful Fragment-to-
Lead (F2L) case studies published in a given year. A tabulated summary of relevant articles …

Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents

Y Zhou, Y Zhang, X Lian, F Li, C Wang… - Nucleic acids …, 2022 - academic.oup.com
Drug discovery relies on the knowledge of not only drugs and targets, but also the
comparative agents and targets. These include poor binders and non-binders for develo** …

Ultrafast Fragment Screening Using Photo-Hyperpolarized (CIDNP) NMR

F Torres, M Bütikofer, GR Stadler… - Journal of the …, 2023 - ACS Publications
While nuclear magnetic resonance (NMR) is regarded as a reference in fragment-based
drug design, its implementation in a high-throughput manner is limited by its lack of …

Brief report: Gender identity differences in autistic adults: Associations with perceptual and socio-cognitive profiles

RJ Walsh, L Krabbendam, J Dewinter… - Journal of autism and …, 2018 - Springer
Prior research has shown an elevation in autism traits and diagnoses in individuals seen for
gender related consultation and in participants self-identifying as transgender. To …

Fragment-based drug discovery supports drugging 'undruggable'protein–protein interactions

ZZ Wang, XX Shi, GY Huang, GF Hao… - Trends in Biochemical …, 2023 - cell.com
Protein–protein interactions (PPIs) have important roles in various cellular processes, but
are commonly described as 'undruggable'therapeutic targets due to their large, flat …

[HTML][HTML] Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

L Song, S Gao, B Ye, M Yang, Y Cheng, D Kang… - … Pharmaceutica Sinica B, 2024 - Elsevier
The main protease (M pro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy
for its high conservation and major role in the virus life cycle. The covalent M pro inhibitor …

High-throughput activity assay for screening inhibitors of the SARS-CoV-2 Mac1 macrodomain

M Dasovich, J Zhuo, JA Goodman, A Thomas… - ACS chemical …, 2021 - ACS Publications
Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of
pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are …

Fragment libraries designed to be functionally diverse recover protein binding information more efficiently than standard structurally diverse libraries

A Carbery, R Skyner, F von Delft… - Journal of Medicinal …, 2022 - ACS Publications
Current fragment-based drug design relies on the efficient exploration of chemical space by
using structurally diverse libraries of small fragments. However, structurally dissimilar …

[HTML][HTML] The conserved macrodomain is a potential therapeutic target for coronaviruses and alphaviruses

AKL Leung, DE Griffin, J Bosch, AR Fehr - Pathogens, 2022 - mdpi.com
Background: Open Access Perspective The Conserved Macrodomain Is a Potential
Therapeutic Target for Coronaviruses and Alphaviruses by Anthony KL Leung 1, 2, 3, 4 …